Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease

European Journal of Clinical Investigation

Volumn 40, Issue 9, 2010, Pages 790-796

  Nakamura, Tsukasa ^a   Fujiwara, Nobuharu ^a   Kawagoe, Yasuhiro ^a   Sugaya, Takeshi ^b   Ueda, Yoshihiko ^c   Koide, Hikaru ^d  

^a Shinmatsudo Central General Hospital   (Japan)

^b RIKEN KOBE INSTITUTE   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

^d KOTO HOSPITAL   (Japan)

Author keywords

Angiotensin II receptor blocker; angiotensin converting enzyme inhibitor; chronic kidney disease; endothelin; liver type fatty acid binding protein

Indexed keywords

ALLOPURINOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM ANTAGONIST; CREATININE; ENALAPRIL; ENDOTHELIN 1; FATTY ACID BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER TYPE FATTY ACID BINDING PROTEIN; PROTEIN; STEROID; TELMISARTAN; UNCLASSIFIED DRUG;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE MEASUREMENT; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMORBIDITY; CONCENTRATION (PARAMETERS); CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY FAILURE; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN DIET; PROTEIN URINE LEVEL; PROTEINURIA; RENAL PROTECTION; SODIUM RESTRICTION; TREATMENT DURATION; URINARY EXCRETION;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CREATININE; ENALAPRIL; ENDOTHELIN-1; FATTY ACID-BINDING PROTEINS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PROTEINURIA;

EID: 77955450907     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02319.x     Document Type: Article

References (36)

1. Yamamoto T, Nakagawa T, Suzuki H, Ohashi N, Fukasawa H, Fujigaki Y et al. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol 2007 18 : 1558 1565.
2. Fernandez-Juarez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luno J. Dual blockade of the rennin-angiotensin system in the progression of renal disease: the need for more clinical trials. J Am Soc Nephrol 2006 17 (12 Suppl. 3 S250 4.
3. Chandar J, Abitbol C, Montane B, Zilleruelo G. Angiotensin blockade as sole treatment for proteinuric kidney disease in children. Nephrol Dial Transplant 2007 22 : 1332 1337.
4. Rysava R, Tesar V, Merta M, for the Czech Group for the Study of Glomerulo-nephritis. Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease. Blood Press Monit 2005 10 : 207 213.
5. Remuzzi A, Remuzzi G. Potential protective effects of telmisartan on renal function deterioration. J Renin Angiotensin Aldosterone Syst 2006 7 : 185 191.
6. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T et al. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med 2005 145 : 125 133.
7. Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 2007 333 : 321 326.
8. Yamamoto T, Noiri E, Ono Y, Doi K, Negishi K, Kamijo A et al. Renal L-type fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol 2007 18 : 2894 2902.
9. Grenda R, Wuhl E, Litwin M, Janas R, Sladowska J, Arbeiter K et al. ESCAPE Trial Group: urinary excretion of endothelin-1 (ET-1), transforming growth factor-1 (TGF-1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial. Nephrol Dial Transplant 2007 22 : 3487 3494.
10. Dhaun N, Ferro CJ, Davenport AP, Haynes WG, Goddard J, Webb DJ. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant 2007 22 : 3228 3234.
11. Vlachojannis JG, Tsakas S, Petropuolou C, Goumenos DS, Alexandri S. Endothelin-1 in the kidney and urine of patients with glomerular disease and proteinuria. Clin Nephrol 2002 58 : 337 343.
12. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y et al. Modification of the MDRD study equation for Japan. Am J Kidney Dis 2007 50 : 927 937.
13. Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease. Hypertens Res 2009 32 : 270 275.
14. Lentine K, Wrone EM. New insights into protein intake and progression of renal disease. Curr Opin Nephrol Hypertens 2004 13 : 333 336.
15. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Shimada N, Koide H. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 2001 21 : 449 454. (Pubitemid 34088200)
16. Nakamura T, Sugaya T, Koide H. Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure. Diabetologia 2007 50 : 490 492.
17. Nakamura T, Inoue T, Suzuki T, Kawagoe Y, Ueda Y, Koide H et al. Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. Hypertens Res 2008 31 : 841 850.
18. Kumai Y, Ooboshi H, Ago T, Ishikawa E, Takada J, Kamouchi H et al. Protective effects of angiotensin II type 1 receptor blocker on cerebral circulation independent of blood pressure. Exp Neurol 2008 210 : 441 448.
19. Yokoyama J, Higuma T, Tomita H, Abe N, Oikawa K, Fujiwara T et al. Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril. Int J Cardiol 2009 132 : 114 120.
20. Barnett A. Preventing renal complications in type 2 diabetes: results of the diabetes exposed to telmisartan and enalapril trial. J Am Soc Nephrol 2006 17 (Suppl. 2 S132 5.
21. Kent DM, Jafar TH, Hayward RA, Tighiouart H, Landa M, de Jong P et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 2007 18 : 1959 1965.
22. Aranda P, Segura J, Ruilope LM, Aranda FJ, Frutos MA, Lopez V et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis 2005 46 : 1074 1079.
23. Mazzali M, Jefferson JA, Ni Z, Vaziri ND, Johnson RJ. Microvascular and tubulointerstitial injury associated with chronic hypoxia-induced hypertension. Kidney Int 2003 63 : 2088 2093.
24. 2 indicating a novel, potentially renoprotective action. Nephron Physiol 2003 94 : 39 46.
25. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005 16 : 3631 3641.
26. D'Amico G, Ferrario F, Rastaldi MP. Tubulointerstitial damage in glomerular diseases: its role in the progression of renal damage. Am J Kidney Dis 1995 26 : 124 132.
27. Chan LY, Leung JC, Tang SC, Choy CB, Lai KN. Tubular expression of angiotensin II receptors and their regulation in IgA nephropathy. J Am Soc Nephrol 2005 16 : 2306 2317.
28. Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 2006 17 : 943 955.
29. Fukui M, Nakamura T, Ebihara I, Makita Y, Osada S, Tomino Y et al. Effects of enalapril on endothelin-1 and growth factor gene expression in diabetic rat glomeruli. J Lab Clin Med 1994 123 : 763 768.
30. Benndorf RA, Appel D, Maas R, Schwedhelm E, Wenzel UO, Böger RH. Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol 2007 50 : 367 371.
31. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J et al. ONTARGET Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008 372 : 547 553.
32. Schmieder R, Delles C, Mimran A. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007 30 : 1351 1356.
33. Woo KT, Chan CM, Tan HK, Choong HL, Foo M, Vathsala A et al. Beneficial effects of high-dose losartan in IgA nephritis. Clin Nephrol 2009 71 : 617 624.
34. Weinergova O, Metelka R, Vymetal J, Konecny K, Kosatikova Z. Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2004 148 : 69 73.
35. Weir MR. Progressive renal and cardiovascular disease: optimal treatment strategies. Kidney Int 2002 62 : 1482 1492.
36. Cupisti A, Rizza GM, D'Alessandro C, Morelli E, Barsotti G. Effect of telmisartan on the proteinuria and circadian blood pressure profile in chronic renal patients. Biomed Pharmacother 2003 57 : 169 172.